News

Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP ...
MPR2h
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
Zacks Investment Research on MSN6h
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...